Da-Yong Lu* and Bin Xu

School of Life Sciences, Shanghai University, Shanghai, China

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.

Received: July 31, 2021; Published: August 12, 2021

Abstract

  Bone cancer and metastasis is difficult to be managed. In the early stage, amputation is widely practiced in the clinic. To avoid this devastating event, drug treatment should be strengthened. Several factors or associations should be noticed for therapeutic promotion and paradigms. This editorial discusses drug development and clinical treatment for bone cancer and metastasis.

Keywords: Bone Cancer; Neoplasm Metastasis; Drug Treatment; Drug Targets; Personalized Medicine

References

1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 168 (2017): 670-691.
2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 112 (2015): 943-947.
3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458.
4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormacy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
5. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene 40 (2021): 1284-1299.
6. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics4 (2021): 55-57.
7. Lu DY., et al. “Cancer Metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
8. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 192-196.
9. Lu DY and Lu TR. “Antimetastatic activities and mechanisms of bisdioxopiperazine compounds”. Anti-Cancer Agent Medicinal Chemistry 7 (2010): 564-570.
10. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
11. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica 3 (2012): 497-508.
12. Agarwal N., et al. “Natural herbs as anticancer drugs”. Journal Pharm Tech, International Journal 3 (2012): 1142-1153.
13. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
14. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice Palliative Medicine International Journal 4 (2019): 125-130.
15. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
16. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics. Woodhead Publishing, Elsevier UK (2014).
17. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology (2015): 282.
18. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
19. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
20. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2017): 101-110.
21. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA4 (2015): 80.
22. Montero J., et al. “Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy”. Cell 160 (2015): 977-989.
23. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Adv Therapeutics (2020): 1900100.
24. Hyman DH., et al. “Implementing genome-driven oncology”. Cell 168 (2017): 584-599.
25. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine2 (2018): 156-163.
26. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry1 (2017): 21-28.
27. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
28. Franssen L., et al. “A mathematical framework for modeling the metastatic spread of cancer”. Bulletin of Mathematical Biology 81 (2019): 1965-2010.
29. Gerlee P and Johanson M. “Infering rates of metastatic dissemination using stochastic network models”. PLOS computational Biology4 (2019): e1006868.
30. Freedman DH. “Hunting for new drugs with AI”. Nature 576 (2019): s49-s53.
31. Lu DY., et al. “Anatomic approaches for cancer metastatic study”. EC Clinical and Experimental Anatomy9 (2020): 32-34.
32. Barani M., et al. “Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma”. Biosensors 11 (2021): 55.

Citation

Citation: Da-Yong Lu and Bin Xu. “Bone Cancer and Metastasis Trials, Drug Treatment". Acta Scientific Orthopaedics 4.9 (2021): 31-33.

Copyright

Copyright: © 2021 Da-Yong Lu and Bin Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.